NxStage Medical, Inc. (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 24,000 shares of NxStage Medical stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $29.64, for a total transaction of $711,360.00. Following the transaction, the president now directly owns 82,903 shares in the company, valued at approximately $2,457,244.92. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of NxStage Medical, Inc. (NXTM) traded down 1.18% during mid-day trading on Tuesday, reaching $29.32. 12,198,787 shares of the company’s stock traded hands. The company’s market cap is $1.93 billion. The company has a 50 day moving average of $24.04 and a 200 day moving average of $25.76. NxStage Medical, Inc. has a 12 month low of $20.45 and a 12 month high of $30.80.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. NxStage Medical had a negative return on equity of 2.31% and a negative net margin of 1.25%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.03) EPS. Analysts expect that NxStage Medical, Inc. will post ($0.03) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/08/nxstage-medical-inc-nasdaqnxtm-president-sells-711360-00-in-stock.html.

Several institutional investors have recently bought and sold shares of the company. Outfitter Advisors LTD. boosted its position in NxStage Medical by 0.4% in the first quarter. Outfitter Advisors LTD. now owns 55,350 shares of the medical device company’s stock worth $1,485,000 after buying an additional 200 shares during the last quarter. Principal Financial Group Inc. boosted its position in NxStage Medical by 1.1% in the first quarter. Principal Financial Group Inc. now owns 28,191 shares of the medical device company’s stock worth $757,000 after buying an additional 303 shares during the last quarter. Chicago Equity Partners LLC boosted its position in NxStage Medical by 0.5% in the first quarter. Chicago Equity Partners LLC now owns 79,930 shares of the medical device company’s stock worth $2,145,000 after buying an additional 390 shares during the last quarter. Legal & General Group Plc boosted its position in NxStage Medical by 3.5% in the second quarter. Legal & General Group Plc now owns 25,349 shares of the medical device company’s stock worth $630,000 after buying an additional 856 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. boosted its position in NxStage Medical by 2.8% in the first quarter. Adams Diversified Equity Fund Inc. now owns 41,000 shares of the medical device company’s stock worth $1,100,000 after buying an additional 1,100 shares during the last quarter. Hedge funds and other institutional investors own 91.11% of the company’s stock.

Several research firms recently weighed in on NXTM. Jefferies Group LLC lowered shares of NxStage Medical from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $33.00 to $30.00 in a research note on Tuesday. Northland Securities restated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a report on Monday. Canaccord Genuity downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a report on Monday. BidaskClub downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Finally, Craig Hallum initiated coverage on shares of NxStage Medical in a report on Tuesday, June 27th. They set a “buy” rating and a $32.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. NxStage Medical has an average rating of “Hold” and an average price target of $29.17.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.